Skip to content
    HCA
    Earnings call· Jun 2025(Q2 FY25)

    HCA Healthcare Q2 FY25 earnings call HCA

    Jul 25, 2025 Source

    Executive summary

    HCA Healthcare Q2 FY25 — Strong Performance Drives Raised Full-Year Guidance

    HCA Healthcare delivered strong Q2 FY25 results, driven by robust revenue growth and improved margins, leading to an increased full-year guidance. The company is actively developing resiliency programs to manage potential impacts from federal policy changes and the expiration of enhanced premium tax credits, while continuing to invest in its network and operational efficiencies. Management expressed confidence in its diversified portfolio and ability to adapt to evolving market dynamics.

    Highlights

    5

    • Diluted earnings per share (adjusted) increased 24% to $6.84.

    • Revenue grew 6.4%, driven by increased demand, improved payer mix, and consistent patient acuity.

    • Adjusted EBITDA margin improved 30 basis points compared to the prior year quarter.

    • Managed care equivalent admissions, including exchanges, grew 4% year-to-date.

    • State supplemental payment net benefit increased by $100 million in Q2 FY25 compared to prior year.

    Concerns

    5

    • Medicaid volumes were down 1.2% year-to-date, and self-pay volumes were up 1.5%, both below expectations.

    • Medicare growth at 3% year-to-date was slightly below expectations.

    • A couple of markets are underperforming, offsetting approximately $50 million of improvements in hurricane-affected markets.

    • The potential expiration of enhanced premium tax credits (EPTCs) at the end of the year poses a risk to insurance coverage.

    • Physician cost inflation, specifically professional fees, increased about 10% year-over-year.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year 2025 Revenue
    $74 billion to $76 billion
    high materiality
    High
    Full-year 2025 Net Income attributable to HCA Healthcare
    $6.11 billion to $6.48 billion
    high materiality
    High
    Full-year 2025 Adjusted EBITDA
    $14.7 billion to $15.3 billion
    high materiality
    High
    Full-year 2025 Diluted Earnings Per Share
    $25.50 to $27.00
    high materiality
    High
    Full-year 2025 Capital Spending
    approximately $5 billion
    medium materiality
    High
    Full-year 2025 Equivalent Admissions Growth
    2% to 3%
    high materiality
    High
    Full-year 2025 Supplemental Payment Net Benefit
    between flat and $100 million favorable year-over-year
    medium materiality
    High
    Long-term guidance (EBITDA growth)
    4% to 6%
    high materiality
    High

    Operational metrics

    43
    Diluted EPS (adjusted)
    $6.8424% increase
    Q2 FY25

    Reflected solid revenue growth, improved payer mix, and consistent patient acuity levels.

    Revenue growth
    6.4%
    Q2 FY25

    Driven by greater demand for services, improved payer mix, and consistent patient acuity levels.

    Adjusted EBITDA margin improvement
    30compared to prior year quarter
    Q2 FY25

    Improved due to a stable operating environment.

    Equivalent admissions growth
    1.7%
    Q2 FY25

    Company-wide equivalent admissions growth.

    Equivalent admissions growth
    2.3%
    YTD June

    Company-wide equivalent admissions growth year-to-date through June.

    Managed care equivalent admissions growth (including exchanges)
    4%
    YTD June

    In line with expectations.

    Medicare equivalent admissions growth
    3%
    YTD June

    Slightly below expectation, but still robust.

    Medicaid volumes
    down 1.2%to prior year
    YTD June

    Below original expectation of flattening or growth.

    Self-pay volumes
    up 1.5%
    YTD June

    Below original expectation of growing at overall volume rate; up almost 7% in '24 over '23.

    Same-facility contract labor as % of total labor costs
    4.3%improved 1% from prior year quarter
    Q2 FY25

    Compared to 4.6% in Q2 FY24. Pre-pandemic levels were around 4.1%-4.2%.

    Supply expense as % of revenue
    increased slightly
    Q2 FY25

    Due primarily to increased spending on cardiac-related devices.

    Adjusted EBITDA growth
    8.4%over prior year quarter
    Q2 FY25

    Substantial portion came from core operations.

    Supplemental payment net benefit increase
    $100 millioncompared to prior year quarter
    Q2 FY25

    Due to prior period reconciliation payments and program accrual timing.

    Capital expenditures
    $1.2 billion
    Q2 FY25

    Part of capital allocation strategy.

    Share repurchases
    $2.5 billion
    Q2 FY25

    Part of capital allocation strategy.

    Dividend
    $171 million
    Q2 FY25

    Part of capital allocation strategy.

    Deferred tax payments
    $850 million
    Q2 FY25

    Due to IRS relief to Tennessee taxpayers after severe weather.

    Guidance increase from state supplemental payments
    $150 million
    FY25

    About half of the $300 million increase in midpoint EBITDA guidance, reflecting Tennessee program approval and better visibility.

    Hurricane-related market improvement
    $100 millionbetter than original flat estimate
    FY25

    Part of the portfolio operational performance improvement contributing to guidance raise.

    Underperforming markets impact
    $50 million
    FY25

    Offsetting some hurricane market improvements.

    Exchange equivalent admissions growth
    15.8%
    YTD June

    A little better than original expectation.

    Commercial managed care book growth (excluding exchanges)
    just short of 1%
    YTD June

    Maybe a little below original guidance.

    Exchange volume growth (Q1 to Q2 FY24)
    14%
    Q1 to Q2 FY24

    Robust growth in the prior year.

    Exchange volume growth (Q1 to Q2 FY25)
    3%
    Q1 to Q2 FY25

    Still saw sequential growth, but lower than prior year.

    Leap year impact on volume
    50
    H1 FY25

    Impact on volume growth in the first half of the year.

    Market share (excluding behavioral health)
    above 28%
    most recent data

    Showing signs of broad-based market share growth across service lines and markets.

    Capital in flight
    $5.5 billion
    current

    Approved capital for network additions, including outpatient facilities and inpatient capacity.

    ACA equivalent admissions as % of total
    8%
    current

    Percentage of total equivalent admissions from ACA exchanges.

    ACA net revenues as % of total
    over 10%
    current

    Percentage of total net revenues from ACA exchanges.

    Targeted savings (Investor Day)
    $600 million to $800 million
    over 5 years

    Targeted savings from resiliency programs, including benchmarking, automation, and shared service platforms.

    Contract labor as % of SWB (pre-pandemic)
    4.1%-4.2%
    pre-pandemic

    Historical level of contract labor as a percentage of salary, wages, and benefits.

    Physician cost inflation (same facility professional fees)
    10%
    YoY

    Elevated cost pressures in the physician component of the business.

    Cardiac procedure volume growth
    5%up
    Q2 FY25

    Reflects productive aspects of the underlying business.

    Obstetrics volumes growth
    3%up
    Q2 FY25

    Reflects productive aspects of the underlying business.

    Neonatal volumes growth
    13%up
    Q2 FY25

    Reflects productive aspects of the underlying business.

    Outpatient surgery volume growth
    down 0.6%
    Q2 FY25

    Better than most recent trends, driven by Medicaid, self-pay, and lower acuity cases.

    Outpatient surgery revenue growth
    7.5%-8%
    Q2 FY25

    Good revenue growth despite volume trends.

    Total outpatient revenue growth
    almost 8%
    Q2 FY25

    All four categories of outpatient book performed well.

    Inpatient surgeries (same-facility) growth
    relatively flat
    Q2 FY25

    Mainly payer mix driven by a drop in Medicaid cases.

    Medicare Advantage as % of total Medicare admissions
    58%
    current

    Reflects the penetration of MA plans.

    Inpatient occupancy
    north of 70%, maybe 73%-74%
    YTD

    Indicates high utilization of inpatient facilities.

    Commercial contracting completion for '26
    80%
    FY26

    Achieving established targets for contracts.

    Commercial contracting completion for '27
    1/3
    FY27

    Achieving established targets for contracts.

    Industry KPIs

    5
    MetricValueDetails
    Utilization trends5% (cardiac); 3% (obstetrics); 13% (neonatal)%
    Same facility volumes1.7% (Q2); 2.3% (YTD)%
    Payer mix supplemental payments$100 millionUSD
    Membership covered lives by line1.7% (Q2); 2.3% (YTD)%
    Adjusted EPS EBITDA leverage guidance$6.84 adjusted EPS; $14.7B-$15.3B adjusted EBITDA guidanceUSD

    Risks & headwinds

    7
    Medicaid component of One Big Beautiful Bill Actnext few years

    Adverse impacts over the next few years are manageable

    Mitigation: Grandfathering provisions for supplemental programs, including previously submitted applications for state-directed payments; phased-in work requirements and supplemental payment program changes; bifurcation of policy between expansion and non-expansion states (60% of Medicaid volumes/revenue in non-expansion states).

    Exchange provisions in the One Big Beautiful Bill Actover the next few years

    Some people will lose insurance coverage

    Mitigation: Financial resiliency program should offset these effects.

    Expiration of enhanced premium tax credits (EPTCs)end of this year

    Potential adverse impact

    Mitigation: Working to develop and execute resiliency programs to offset as much as possible any adverse impact; advocating strongly for their extension.

    Underperforming marketsFY25

    Approximately $50 million impact

    Mitigation: Confidence in plans in place to address challenges; seasoned leaders in hospitals and divisions are responding to competitive dynamics and service mix changes; expected to recover in the second half of the year.

    Labor market tightness in North Carolinarecent

    Required more contract labor

    Mitigation: Teams are dealing with operational requirements and patient needs effectively; continued focus on improving quality and engaging stakeholders.

    Physician cost inflationrecent

    Same facility professional fees increased about 10% year-over-year

    Mitigation: Acknowledged as a component of the business still dealing with greater than inflationary levels of cost pressure; no specific mitigation detailed beyond general cost management.

    Hurricane impact (prior year)Q3 and Q4 FY24

    $250 million

    Mitigation: Recovery in hurricane-affected markets is going better than anticipated, contributing $100 million better to FY25 guidance than originally estimated.

    What to watch in Q3 FY25

    5

    EPTCs extension outcome

    Q4 FY25
    CurrentScheduled to expire end of year
    TargetExtension or clear policy direction

    Why it matters

    The outcome of EPTC extension will significantly impact insurance coverage and HCA's payer mix, requiring adjustments to financial resiliency programs.

    We continue to advocate strongly for their extension. But at this point, we do not know what the outcome will be.

    Q&A highlights

    6

    Clarification on the $300 million EBITDA guidance raise, specifically if the Tennessee DPP is included, and commentary on the slight downgrade in admissions guidance and underlying demand.

    Mike Marks confirmed that about half of the $300 million EBITDA increase is from state supplemental payments, including the Tennessee DPP. The other half is from portfolio performance, with hurricane-related markets performing better than anticipated, partially offset by underperforming markets. He detailed volume trends, noting Medicaid and self-pay were below expectations, and Medicare was robust but slightly slower than anticipated. Sam Hazen emphasized the qualitative strength of volume growth, highlighting increases in cardiac, obstetrics, and neonatal procedures across a diversified portfolio.

    “about half of that is from state supplemental payment programs, and that does reflect the approval of the new Tennessee program.”

    asked by Albert Rice · answered by Mike Marks

    2 min read6 chapters

    Detailed Narrative

    01

    Q2 Financial Performance and Guidance Update

    HCA Healthcare reported strong Q2 FY25 financial results, with adjusted diluted EPS increasing 24% to $6.84 and revenue growing 6.4%. This performance was attributed to increased demand, an improved payer mix, and consistent patient acuity. The company raised its full-year 2025 guidance for revenue, net income, adjusted EBITDA, and diluted EPS, reflecting confidence in the positive demand environment and strategic initiatives. The updated guidance also projects equivalent admissions growth of 2% to 3% for the full year.

    02

    Federal Policy Environment and Resiliency Programs

    Management discussed the implications of the One Big Beautiful Bill Act, noting that adverse impacts from the Medicaid component are expected to be manageable due to grandfathering provisions and phased-in changes. While some people may lose insurance coverage due to exchange provisions and the potential expiration of enhanced premium tax credits (EPTCs) at year-end, HCA is developing financial resiliency programs to offset these effects. The company will provide more details on these efforts with its 2026 guidance in Q4 FY25.

    03

    Volume Trends and Payer Mix Dynamics

    Equivalent admissions increased 1.7% for the quarter and 2.3% year-to-date. Managed care equivalent admissions, including exchanges, grew 4% year-to-date, aligning with expectations. However, Medicaid volumes were down 1.2% and self-pay volumes were up 1.5% year-to-date, both below original expectations. Medicare growth was 3% year-to-date, slightly below expectations. Despite some lower-acuity case declines, cardiac procedure volume was up 5%, obstetrics up 3%, and neonatal up 13%, indicating strength in higher-acuity services.

    04

    Operational Efficiency and Cost Management

    Adjusted EBITDA margin improved 30 basis points year-over-year, with salary and benefits and other operating expenses improving as a percentage of revenue. Same-facility contract labor decreased to 4.3% of total labor costs in Q2 FY25 from 4.6% in Q2 FY24. Supply expense increased slightly due to cardiac-related devices. The company continues to focus on operational improvements, including case management, automation, and digital transformation, as part of its broader resiliency efforts.

    05

    Capital Allocation and Investment Strategy

    HCA deployed a balanced capital allocation strategy, with $1.2 billion in capital expenditures, $2.5 billion in share repurchases, and $171 million in dividends during Q2 FY25. The company deferred approximately $850 million in tax payments to Q4 due to IRS relief for Tennessee taxpayers. HCA has $5.5 billion worth of capital in flight for network expansion, including outpatient facilities and inpatient capacity, and continues to seek opportunities for greenfield projects and acquisitions.

    06

    Market Share and Competitive Dynamics

    HCA reported sustained market share gains, with market share (excluding behavioral health) above 28%. 14 out of 15 domestic divisions grew their admissions. While a couple of divisions are underperforming due to competitive dynamics and service mix changes, management expressed confidence in their ability to recover. The company's diversified portfolio and network model are seen as key strengths in maintaining competitiveness and meeting patient demand.

    AI-generated summary of the company’s earnings call. Not investment advice.